MEDS
DataMEDS AI, Inc.
There isn't enough reported data to score MEDS yet.
MEDS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
MEDS's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
MEDS PE Valuation
MEDS has no meaningful PE right now: it lost money over the past year.
MEDS Forward outlook
There aren't enough analyst estimates for MEDS to show an outlook.
MEDS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$45.63 | -$3.16 |
| Q1 2026 | -$44.00 | -$6.48 |
| Q4 2025 | -$71.50 | -$63.16 |
| Q3 2025 | -$63.67 | -$46.90 |
| Q2 2025 | -$42.47 | -$26.63 |
| Q1 2025 | -$37.52 | -$21.82 |
MEDS lost $45.63 per share over the past year, about the same as its loss the year before.
MEDS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.8M | -77% |
| Q1 2026 | $1.6M | -86% |
| Q4 2025 | $1.7M | -87% |
| Q3 2025 | $3M | -47% |
| Q2 2025 | $7.8M | -25% |
| Q1 2025 | $10.9M | +37% |
| Q4 2024 | $12.4M | -64% |
MEDS's revenue has slid since its 2023 peak: $2M last quarter, down 77% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -413% | -342 points |
| Q1 2026 | -386% | -97 points |
| Q4 2025 | -1518% | -1487 points |
| Q3 2025 | -1047% | -1016 points |
| Q2 2025 | -71% | -49 points |
| Q1 2025 | -289% | -270 points |
| Q4 2024 | -30% | -0.2 points |
| Q3 2024 | -31% | N/A |
MEDS's operating margin was −413% last quarter, down 342 points from the same quarter a year ago.
MEDS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2.9M | -$815.2K |
| Q1 2026 | -$3.4M | -$2.1M |
| Q4 2025 | -$6.3M | -$3.5M |
| Q3 2025 | -$1.1M | -238% |
| Q2 2025 | -$2.1M | -2773% |
| Q1 2025 | -$1.3M | +$8.8M |
| Q4 2024 | -$2.8M | -$2.3M |
| Q3 2024 | $820.5K | +627% |
MEDS has burned cash in most quarters: −$14M over the past year, against −$5M the year before.
MEDS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +23% | +482K shares |
| 1 year | +148% | +1.5M shares |
MEDS has 3M diluted shares, up 148% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
MEDS Net Leverage
MEDS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
MEDS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 4.4 | Oversold |
MEDS's weekly RSI is 35 (neutral) and its Stochastic is 4 (oversold).
MEDS PE vs Healthcare Sector
MEDS has no meaningful PE right now: it lost money over the past year.
MEDS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.32 | 62% below |
| 20 week MA | $2.24 | 61% below |
| 50 week MA | $7.75 | 89% below |
| 100 week MA | $41.5 | 98% below |
MEDS is in a downtrend: it's below all four of its weekly moving averages, and 98% below its 100-week average.
MEDS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $12.8 | $7.59 | -41% |
| 2025 | $7.59 | $20.2 | +167% |
| 2026 YTD | $20.2 | $0.87 | -96% |
MEDS's yearly returns have swung widely, from +167% in 2025 to −41% in 2024. It's down 96% so far in 2026.